Home › Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
 

Keywords :   


Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

2016-08-08 23:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in of results study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.05Visitor Registration Open for Coatings for Africa
07.05OQ Chemicals Resumes Operations in German Plants
07.05Polychem Powder Coatings Moves into New Production Facility
07.05Cyngientappoints Jake Chaney VP of sales
07.05Printing United Alliance launches new iLEARNING+ courses
07.05Huggies Launches Skin Essentials Diaper
07.05Meisheng Starts Up Needlepunch Line
07.05Clemens Food Group expands pork production with Kunzler acquisition
More »